DT402 not checked
Definium Therapeutics US, Inc. · MM402
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA”In the company’s words, NCT07303907 on ClinicalTrials.gov
- Tested for
- Autism Spectrum Disorder, ASD
- Main trialPhase 2
- “A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder”In the company’s words, NCT07303907 on ClinicalTrials.gov
- Other names
- MM402 · R-MDMA · MDMA
Other drugs for Autism Spectrum Disorder
- CM-ATCuremark · Phase 3
- NTI164Fenix Innovation Group · Phase 3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- ML-004MapLight Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes2
Last 90 days- 13 NovStatus changed: Recruiting to Completed · ClinicalTrials.gov NCT07303907
- 13 NovCompletion date moved: 2027-08 to 2026-09-16 · ClinicalTrials.gov NCT07303907
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 16 Sep 2026 | A Phase 2A Trial of DT402 for Autism Spectrum Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026